STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

Merck to Acquire Caraway Therapeutics, Inc.

Rhea-AI Summary
Merck (MRK) to Acquire Caraway Therapeutics for Up to $610 Million in an Effort to Develop Treatments for Neurodegenerative Diseases. The acquisition will further advance Merck's research and development capabilities in pursuing innovative approaches for the treatment of genetically defined neurodegenerative and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
acquisition
-
News

Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Merck (NYSE: MRK) to Participate in Fireside Chat at Evercore ISI HealthCONx Conference on Nov 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
-
News

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Rhea-AI Summary
Merck (NYSE: MRK) receives FDA approval for KEYTRUDA in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma. The approval is based on the Phase 3 KEYNOTE-859 trial, showing a 22% reduction in the risk of death and a median overall survival of 12.9 months. Serious adverse reactions occurred in 45% of patients receiving KEYTRUDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
fda approval
News

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

Rhea-AI Summary
Defence Therapeutics Inc. (OTCPK: DTCFF): Oncology drugs market growth is driven by rising cancer prevalence, new drug launches, and research activities. The global oncology drugs market size is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0%. Defence Therapeutics submitted an Investigational New Drug (IND) application for AccuTOX®, an injectable anticancer molecule, with potential to combat solid tumors. The company aims to advance AccuTOX® into clinical trials, with the primary objective of identifying therapeutic dosing range for co-administration with Opdulag®, a BMS product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Rhea-AI Summary
Merck (MRK) announces positive opinion from CHMP for approval of KEYTRUDA in combination with gemcitabine and cisplatin for the first-line treatment of biliary tract carcinoma, based on Phase 3 KEYNOTE-966 trial results, showing significant improvement in overall survival (OS) compared to chemotherapy alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
News

Merck to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary
MRK: Merck's CFO to Speak at Jefferies London Healthcare Conference on Nov. 16, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
News

Merck to Participate in the UBS BioPharma Conference

Rhea-AI Summary
Merck (NYSE: MRK) announced that Jannie Oosthuizen, president, Human Health U.S., will participate in a fireside chat at the UBS BioPharma Conference on Nov. 8, 2023, at 12:00 p.m. EST. The presentation will be available via live audio webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
-
News

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has been approved by the FDA for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. The approval was based on the Phase 3 KEYNOTE-966 trial, which showed a 17% reduction in the risk of death when KEYTRUDA was combined with gemcitabine and cisplatin compared to chemotherapy alone. Median overall survival was 12.7 months for KEYTRUDA plus chemotherapy versus 10.9 months for chemotherapy alone. This marks the sixth gastrointestinal cancer indication for KEYTRUDA in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
fda approval
-
News

KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy

Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy in patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy. The Phase 3 KEYNOTE-564 trial demonstrated a significant disease-free survival benefit and met its key secondary endpoint of OS compared to placebo. The safety profile of KEYTRUDA was consistent with previous studies. Results will be presented at a medical meeting and submitted to regulatory authorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
News

Merck Announces Third-Quarter 2023 Financial Results

Rhea-AI Summary
Merck announces financial results for Q3 2023, with total worldwide sales of $16.0 billion, an increase of 7% from Q3 2022. Key highlights include the growth of KEYTRUDA sales by 17% to $6.3 billion and the collaboration agreement with Daiichi Sankyo for three clinical-stage ADC candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
earnings

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.16 as of November 25, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 256.1B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#34 Ranked by Market Cap
#933 Ranked by Dividends

MRK Stock Data

256.11B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH